Compare VOYA & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VOYA | PTGX |
|---|---|---|
| Founded | 1975 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Life Insurance | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.7B | 5.4B |
| IPO Year | 2013 | 2016 |
| Metric | VOYA | PTGX |
|---|---|---|
| Price | $75.93 | $86.21 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 9 |
| Target Price | $83.64 | ★ $90.56 |
| AVG Volume (30 Days) | 753.6K | ★ 932.2K |
| Earning Date | 02-03-2026 | 02-20-2026 |
| Dividend Yield | ★ 2.49% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 5.82 | 0.72 |
| Revenue | ★ $8,088,000,000.00 | $209,217,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.02 | $288.98 |
| P/E Ratio | ★ $12.98 | $121.05 |
| Revenue Growth | ★ 2.91 | N/A |
| 52 Week Low | $52.43 | $33.70 |
| 52 Week High | $78.00 | $96.54 |
| Indicator | VOYA | PTGX |
|---|---|---|
| Relative Strength Index (RSI) | 61.97 | 46.55 |
| Support Level | $74.26 | $84.11 |
| Resistance Level | $76.34 | $89.61 |
| Average True Range (ATR) | 1.30 | 3.03 |
| MACD | 0.05 | -0.73 |
| Stochastic Oscillator | 81.11 | 17.10 |
Voya Financial Inc is a financial services company, which, through its subsidiaries, provides various investment, insurance, and retirement solutions to individual and institutional clients in the United States. Its products and services include tax savings plans, individual retirement accounts, group life insurance plans, and employee benefits products, among others. The company tailors each of its products to the needs of its customer base. It operates its business through three principal lines: Wealth Solutions, Investment Management, and Health Solutions The Wealth segment generates roughly half of the company's revenue.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.